Literature DB >> 7791555

Reduced N-acetylaspartate content in the frontal part of the brain in patients with probable Alzheimer's disease.

P Christiansen1, A Schlosser, O Henriksen.   

Abstract

The fully relaxed water signal was used as an internal standard in a STEAM experiment to calculate the concentrations of the metabolites: N-acetylaspartate (NAA), creatine + phosphocreatine [Cr + PCr], and choline-containing metabolites (Cho) in the frontal part of the brain in 12 patients with probable Alzheimer's disease. Eight age-matched healthy volunteers served as controls. Furthermore, T1 and T2 relaxation times of the metabolites and signal ratios: NAA/Cho, NAA/[Cr + PCr], and [Cr + PCr]/Cho at four different echo times (TE) and two different repetition times (TR) were calculated. The experiments were carried out using a Siemens Helicon SP 63/84 wholebody MR-scanner at 1.5 T. The concentration of NAA was significantly lower in the patients with probable Alzheimer's disease than in the healthy volunteers. No significant difference was found for any other metabolite concentration. For the signal ratios the only statistically significant difference was that the NAA/Cho ratio at TE = 92 ms and TR = 1.6 s was lower in the patients with probable Alzheimer's disease compared with the control group. A trend towards a longer T2 relaxation time for NAA in the patients with probable Alzheimer's disease than among the healthy volunteers was found, but no significant difference was found concerning the T1 and T2 relaxation times.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7791555     DOI: 10.1016/0730-725x(94)00113-h

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  9 in total

1.  Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.

Authors:  Pedro J Modrego; Miguel A Pina; Nicolás Fayed; Marcos Díaz
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

2.  Magnetization transfer imaging and proton MR spectroscopy in the evaluation of axonal injury: correlation with clinical outcome after traumatic brain injury.

Authors:  G Sinson; L J Bagley; K M Cecil; M Torchia; J C McGowan; R E Lenkinski; T K McIntosh; R I Grossman
Journal:  AJNR Am J Neuroradiol       Date:  2001-01       Impact factor: 3.825

Review 3.  Various MRS application tools for Alzheimer disease and mild cognitive impairment.

Authors:  F Gao; P B Barker
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-17       Impact factor: 3.825

Review 4.  Magnetic resonance imaging and magnetic resonance spectroscopy in dementias.

Authors:  Y Y Hsu; A T Du; N Schuff; M W Weiner
Journal:  J Geriatr Psychiatry Neurol       Date:  2001       Impact factor: 2.680

5.  Subcortical ischemic vascular dementia: assessment with quantitative MR imaging and 1H MR spectroscopy.

Authors:  A A Capizzano; N Schuff; D L Amend; J L Tanabe; D Norman; A A Maudsley; W Jagust; H C Chui; G Fein; M R Segal; M W Weiner
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

6.  Potential clinical impact of multiparametric quantitative MR spectroscopy in neurological disorders: A review and analysis.

Authors:  Ivan I Kirov; Assaf Tal
Journal:  Magn Reson Med       Date:  2019-08-08       Impact factor: 4.668

7.  Alzheimer disease: quantitative H-1 MR spectroscopic imaging of frontoparietal brain.

Authors:  N Schuff; D L Amend; D J Meyerhoff; J L Tanabe; D Norman; G Fein; M W Weiner
Journal:  Radiology       Date:  1998-04       Impact factor: 11.105

8.  What is the optimal schedule for multiparametric MRS? A magnetic resonance fingerprinting perspective.

Authors:  Alexey Kulpanovich; Assaf Tal
Journal:  NMR Biomed       Date:  2019-12-09       Impact factor: 4.478

Review 9.  Lower brain and blood nutrient status in Alzheimer's disease: Results from meta-analyses.

Authors:  Martijn C de Wilde; Bruno Vellas; Elodie Girault; Aysun Cetinyurek Yavuz; John W Sijben
Journal:  Alzheimers Dement (N Y)       Date:  2017-06-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.